Principal Financial Group Inc. Has $1.62 Million Stock Position in Evolent Health, Inc. (NYSE:EVH)

Principal Financial Group Inc. increased its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 268.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,382 shares of the technology company’s stock after purchasing an additional 41,788 shares during the period. Principal Financial Group Inc.’s holdings in Evolent Health were worth $1,623,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Harbor Capital Advisors Inc. grew its holdings in shares of Evolent Health by 140.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock valued at $11,946,000 after buying an additional 246,400 shares during the period. US Bancorp DE grew its stake in Evolent Health by 180.3% in the third quarter. US Bancorp DE now owns 6,579 shares of the technology company’s stock valued at $186,000 after acquiring an additional 4,232 shares during the period. Values First Advisors Inc. increased its holdings in shares of Evolent Health by 21.0% in the third quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company’s stock worth $909,000 after acquiring an additional 5,583 shares in the last quarter. Moody Aldrich Partners LLC acquired a new stake in shares of Evolent Health during the third quarter worth about $1,421,000. Finally, Friedenthal Financial bought a new position in shares of Evolent Health during the 3rd quarter valued at about $723,000.

Evolent Health Stock Performance

NYSE:EVH opened at $11.25 on Friday. The stock has a 50 day simple moving average of $23.26 and a 200 day simple moving average of $23.77. The stock has a market cap of $1.31 billion, a P/E ratio of -12.36 and a beta of 1.58. Evolent Health, Inc. has a 1-year low of $11.17 and a 1-year high of $35.00. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Analyst Ratings Changes

EVH has been the topic of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $20.00 target price on shares of Evolent Health in a report on Tuesday, November 12th. JPMorgan Chase & Co. cut their price objective on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $38.00 to $16.00 in a report on Friday, November 8th. Citigroup reduced their price objective on Evolent Health from $33.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Oppenheimer cut their target price on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $25.90.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.